[New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19].
Ter Arkh
; 94(7): 872-875, 2022 Aug 12.
Article
in Russian
| MEDLINE | ID: covidwho-2026363
ABSTRACT
The specific feature of new coronavirus infection (COVID-19) is high risk of hyperinflammatory response or cytokine storm development, which underly the pathogenesis of several life-threatening conditions and determine the disease outcomes. Pathophysiological features of COVID-19 justify the search of effective drugs capable to control the hyperinflammatory response. AIM:
To evaluate the efficacy and safety of Aterixen (1-[2-(1-Ðethylimidazol-4-yl)-ethyl]perhydroazin-2,6-dion) for achieving clinical improvement in adult patients hospitalized with moderate and severe COVID-19. MATERIALS ANDMETHODS:
Multicenter, adaptive, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of Aterixen , tablets, 100 mg, in patients with COVID-19. The study analysis included 116 patients who, by randomization, were divided into 2 groups 57 patients were included in the Aterixen drug group and 59 patients were in the placebo group. RESULTS ANDCONCLUSION:
Obtained results have shown high efficacy and statistically significant superiority of Aterixen over placebo. Thus, it allows us to consider it as viable medication for COVID-19 pathogenetic therapy.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Humans
Language:
Russian
Journal:
Ter Arkh
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS